ArticleEJHaem2021

Reduced alpha diversity of the oral microbiome correlates with short progression-free survival in patients with relapsed/refractory multiple myeloma treated with ixazomib-based therapy (AGMT MM 1, phase II trial).

Heinz Ludwig et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.